HK1021316A1 - Use of mycobacterium vaccae for treating chronic fatigue syndrome - Google Patents

Use of mycobacterium vaccae for treating chronic fatigue syndrome

Info

Publication number
HK1021316A1
HK1021316A1 HK99106112A HK99106112A HK1021316A1 HK 1021316 A1 HK1021316 A1 HK 1021316A1 HK 99106112 A HK99106112 A HK 99106112A HK 99106112 A HK99106112 A HK 99106112A HK 1021316 A1 HK1021316 A1 HK 1021316A1
Authority
HK
Hong Kong
Prior art keywords
chronic fatigue
fatigue syndrome
treating chronic
mycobacterium vaccae
vaccae
Prior art date
Application number
HK99106112A
Other languages
English (en)
Inventor
Graham Arthur William Rook
John Lawson Stanford
Alimuddin Ismail Zumla
Original Assignee
Stanford Rook Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626215.9A external-priority patent/GB9626215D0/en
Priority claimed from GBGB9626859.4A external-priority patent/GB9626859D0/en
Application filed by Stanford Rook Ltd filed Critical Stanford Rook Ltd
Publication of HK1021316A1 publication Critical patent/HK1021316A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK99106112A 1996-12-18 1999-12-24 Use of mycobacterium vaccae for treating chronic fatigue syndrome HK1021316A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9626215.9A GB9626215D0 (en) 1996-12-18 1996-12-18 A therapeutic agent and its use
GBGB9626859.4A GB9626859D0 (en) 1996-12-24 1996-12-24 Medical treatment
PCT/GB1997/003460 WO1998026790A1 (en) 1996-12-18 1997-12-17 Mycobacterium vaccae for down-regulation of the th2 activity of the immune system

Publications (1)

Publication Number Publication Date
HK1021316A1 true HK1021316A1 (en) 2000-06-09

Family

ID=26310662

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99106112A HK1021316A1 (en) 1996-12-18 1999-12-24 Use of mycobacterium vaccae for treating chronic fatigue syndrome

Country Status (18)

Country Link
EP (1) EP0951289B1 (fi)
JP (1) JP4358306B2 (fi)
KR (1) KR100533818B1 (fi)
CN (1) CN1129453C (fi)
AP (1) AP1044A (fi)
AT (1) ATE307600T1 (fi)
AU (1) AU730548B2 (fi)
BR (1) BR9713959A (fi)
CA (1) CA2273848C (fi)
DE (1) DE69734461T2 (fi)
DK (1) DK0951289T3 (fi)
ES (1) ES2251744T3 (fi)
FI (1) FI120136B (fi)
HK (1) HK1021316A1 (fi)
NO (1) NO321202B1 (fi)
NZ (1) NZ336147A (fi)
RU (1) RU2197989C2 (fi)
WO (1) WO1998026790A1 (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361776B1 (en) * 1999-12-06 2002-03-26 Genesis Research & Development Corp. Ltd. Compounds isolated from M. vaccae and their use in modulation of immune responses
US20030180260A1 (en) * 2000-06-19 2003-09-25 Clancy Robert Llewellyn Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002066055A1 (en) * 2001-02-20 2002-08-29 Maruho Co., Ltd. NOVEL MEDICINAL USE OF α ANTIGEN OR α ANTIGEN GENE
MX2017016931A (es) * 2015-06-24 2018-09-26 Immodulon Therapeutics Ltd Inhibidor del punto de regulacion y un mycobaterium de celula entera para uso en la terapia del cancer.
US11077179B2 (en) 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
GB9219425D0 (en) * 1992-09-14 1992-10-28 Univ London Therapeutic agent and its use
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
AUPM864894A0 (en) * 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders

Also Published As

Publication number Publication date
AP9901553A0 (en) 1999-06-30
DK0951289T3 (da) 2006-03-13
FI991384A0 (fi) 1999-06-17
KR100533818B1 (ko) 2005-12-07
NO321202B1 (no) 2006-04-03
JP2001506256A (ja) 2001-05-15
DE69734461D1 (de) 2005-12-01
FI991384A (fi) 1999-06-17
WO1998026790A1 (en) 1998-06-25
ATE307600T1 (de) 2005-11-15
AU7735598A (en) 1998-07-15
NO992957L (no) 1999-08-10
FI120136B (fi) 2009-07-15
EP0951289A1 (en) 1999-10-27
CN1246056A (zh) 2000-03-01
JP4358306B2 (ja) 2009-11-04
NO992957D0 (no) 1999-06-17
EP0951289B1 (en) 2005-10-26
ES2251744T3 (es) 2006-05-01
AP1044A (en) 2002-02-18
CN1129453C (zh) 2003-12-03
NZ336147A (en) 2001-03-30
CA2273848A1 (en) 1998-06-25
DE69734461T2 (de) 2006-07-06
CA2273848C (en) 2008-02-19
KR20000069518A (ko) 2000-11-25
AU730548B2 (en) 2001-03-08
RU2197989C2 (ru) 2003-02-10
BR9713959A (pt) 2000-04-11

Similar Documents

Publication Publication Date Title
EP0672401A3 (en) Heat treatment device.
ZA972929B (en) Systems for the treatment of commingled wastes and methods for treating commingled wastes.
EP0717592A4 (en) METHOD AND COMPOSITION FOR TREATING THE APATHIE DEMOTIVATION SYNDROME
EP0703282A3 (en) Surface treatment composition
GB9620877D0 (en) Metal surface treatment
EP0742849A4 (en) SURFACE TREATMENT AGENT FOR ZINC PLATED STEEL
EP1014975A4 (en) METHOD FOR TREATING CHRONIC FATIGUE SYNDROME AND FIBROMYALGIA WITH BUPRENORPHINE
EP0653271A4 (en) DEVICE FOR SURFACE TREATMENT.
GB9605828D0 (en) Treatment method
HK1021316A1 (en) Use of mycobacterium vaccae for treating chronic fatigue syndrome
EP0776380A4 (en) SURFACE TREATED IRON BEARING
HK1022267A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
EP0860867A4 (en) SURFACE TREATMENT FOR MICRO-MACHINING
GB9803880D0 (en) Massage mat
ZA973843B (en) Treatment of asthma with TNFR-lg.
EP0888780A4 (en) COMPOSITION FOR TREATING CONTACT LENSES AND METHOD FOR USE THEREOF
EP0546126A4 (en) Method and compositions for diagnosing and treating chronic fatigue immunodysfunction syndrome
HUP9902802A3 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
GB9416410D0 (en) Effluent treatment
EP1015001A4 (en) METHOD FOR TREATING THE IMPETIGO AND SIMILAR DISEASES
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
AU5374898A (en) The use of oxandrolone in the treatment of chronic fatigue syndrome
GB9614705D0 (en) Fuel treatment device
GB9403127D0 (en) The treatment of solid wastes
EP0979653A4 (en) MEDICINE AGAINST CHRONIC FATIGUE SYNDROME

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111217